Zimbabwe has declined a substantial US health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' demand for sensitive biological samples.
This move came to light after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman later explained that the US was demanding access to health data for scientific study and profit while was unwilling to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further dialogue to find a agreement acceptable to all parties so the country's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a high court blocked a related deal with the US following legal challenges were filed about the security of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and accountability.
According to reports, 16 African countries have so far agreed to these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research without any certainty that the resulting innovations would be accessible to our citizens should a new pandemic arise."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending systems already set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is designed to guarantee that when a country provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future co-operation might be structured in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the government's concerns, but urged that negotiations must proceed considering much of the nation's Aids initiatives were funded by international support.
"If technical issues arise, including those relating to information security or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
This impasse underscores the continuing challenges between accepting much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.